Completed PHASE3 INTERVENTIONAL 2-arm NCT01122641

The Vascular Effects of Vildagliptin in Insulin Resistant Individuals

Does Modulating the Gut Hormones, Incretins, Modify Vascular Function, Thereby Reducing the Risk of Vascular Complications in Insulin Resistant Individuals?

Sponsor: National Institute for Health Research, United Kingdom

Conditions Insulin Resistance Microvascular Disease

Interventions Placebo Vildagliptin

Updated 6 times since 2017 Last updated: Apr 24, 2017 Started: May 31, 2010 Primary completion: Aug 1, 2014 Completion: Aug 1, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01122641, this PHASE3 trial focuses on Insulin Resistance and Microvascular Disease and remains completed. Sponsored by National Institute for Health Research, United Kingdom, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
May 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Unknown Status PHASE3

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute for Health Research, United Kingdom
Novartis Pharmaceuticals
Royal Devon and Exeter NHS Foundation Trust

Data source: Royal Devon and Exeter NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Exeter, United Kingdom